Dr Reddy's, GSK tie up for emerging markets

16 Jun 2009 Evaluate

Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories (DRL) has entered into a partnership with GlaxoSmithKline (GSK) to develop and market select products across emerging markets outside India. Under the terms of the agreement, which is effective immediately, GSK will gain access to DRL’s diverse portfolio and a pipeline of more than 100 branded pharmaceuticals in fast-growing therapeutic segments, such as cardiovascular, diabetes, oncology, gastroenterology and pain management.

 

The products will be manufactured by DRL and will be licensed and supplied to GSK in various emerging markets such as Africa, West Asia, Latin America and Asia-Pacific, excluding India. Revenues will be reported by GSK and will be shared with DRL as per agreed terms. In certain markets, products will be co-marketed by DRL and GSK.

 

This is another significant step forward to grow and diversify business in emerging markets. Growth in both population and economic prosperity is leading to increased demand for branded pharmaceuticals. This new alliance will combine Dr Reddy’s portfolio of high quality branded pharmaceuticals together with GSK’s extensive sales and marketing capabilities.

crackcrack

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.